Who
Joanne Wendy Kim
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, BioVie.
In numbers
- Trades disclosed
- 18
- Buys
- 2
- Sells
- 0
- Bought
- $22K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Oct 2019
- Last trade
- 28 Aug 2026
- Last filed
- 28 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Aug 2026filed 28 Aug 2026 | BIVI BioVieBiotechnology | SEC FORM 4 Bought | $5,4502,500 at $2.18 | filing |
| 28 Aug 2026filed 28 Aug 2026 | BIVI BioVieBiotechnology | SEC FORM 4 Bought | $5,4502,500 at $2.18 | filing |
| 5 Jan 2026filed 9 Jan 2026 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,100 at $0.00 | filing |
| 5 Jan 2026filed 9 Jan 2026 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,100 at $0.00 | filing |
| 20 Dec 2024filed 7 Jan 2025 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,417 at $0.00 | filing |
| 24 Jun 2024filed 12 Jul 2024 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —99,000 at $0.00 | filing |
| 24 Jun 2024filed 12 Jul 2024 | BIVI BioVieBiotechnology | SEC FORM 4 Code A | —73,000 at $0.00 | filing |
| 24 Jun 2024filed 12 Jul 2024 | BIVI BioVieBiotechnology | SEC FORM 4 Code F | $8,57818,250 at $0.47 | filing |
| 15 Feb 2024filed 12 Jul 2024 | BIVI BioVieBiotechnology | SEC FORM 4 Code F | $2,9222,476 at $1.18 | filing |
| 11 Dec 2023filed 13 Dec 2023 | BIVI BioVieBiotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 7 Jun 2023filed 3 Jul 2023 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 16 Feb 2023filed 12 Jul 2024 | BIVI BioVieBiotechnology | SEC FORM 4 Code F | $14K2,476 at $5.51 | filing |
| 16 Feb 2023filed 22 Feb 2023 | BIVI BioVieBiotechnology | SEC FORM 4 Code F | $15K2,476 at $6.12 | filing |
| 23 Nov 2022filed 18 Jan 2023 | BIVI BioVieBiotechnology | SEC FORM 4 Code A | —39,624 at $0.00 | filing |
| 7 Dec 2021filed 9 Dec 2021 | BIVI BioVieBiotechnology | SEC FORM 4 Bought | $11K2,000 at $5.40 | filing |
| 20 Aug 2021filed 16 Sep 2021 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —124,167 at $0.00 | filing |
| 1 Oct 2020filed 21 Oct 2020 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | $7,632800 at $9.54 | filing |
| 1 Oct 2019filed 21 Oct 2020 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | $7,000800 at $8.75 | filing |
News
BioVie reports positive Phase 2 Parkinson's data for bezisterimBIVI · proactiveinvestors.com · 20 Oct 2026BioVie's Bezisterim Shows Positive Signals In Long COVID Patients With Greater Symptom BurdenBIVI · rttnews.com · 19 Oct 2026BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroupsBIVI · proactiveinvestors.com · 19 Oct 2026
0 headlines in the last 90 days name Joanne Wendy Kim; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.